Last reviewed · How we verify

NCT06259630: NEVE

Nicotine Virtual Reality Conditioned Place Preference

Withdrawn Phase 4 Last updated 14 February 2024
What this trial tests

Phase 4 trial testing Nicotine in Nicotine Addiction. Withdrawn.

Timeline
3 November 2015
Primary endpoint
22 June 2018
22 June 2018

Quick facts

Lead sponsorUniversity of Chicago
PhasePhase 4
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposebasic science
Start date3 November 2015
Primary completion22 June 2018
Estimated completion22 June 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Chicago

Who can join

Adults 18 to 35, any sex, with Nicotine Addiction or Nicotine Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this between-subjects, placebo controlled, double-blind study, the investigators will examine the effects of low oral doses of nicotine on the learning and extinction of a conditioned place preference acquired in a virtual reality environment by healthy human subjects. Physiological and subjective responses to the drug will also be monitored.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Nicotine

Trials testing the same drug.

Other recruiting trials for Nicotine Addiction

Currently open trials in the same condition.

Other University of Chicago trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06259630.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing